stockrowAMNEAL PHARMACEUTICALS, INC.
AMRX Healthcare Drug Manufacturers Specialty & Generic
AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.
- Revenue
- +9.96%
- EPS
- +267.0%
- Free cash flow
- −50.9%
- Total debt
- +23.8%
Quarter to September 2026, against a year earlier
Follow AMRX
Alert me
AMNEAL PHARMACEUTICALS, INC. (AMRX) Return on equity
AMNEAL PHARMACEUTICALS, INC.'s return on equity over the twelve months to 30 September 2026 was −53,107.2%, down 53027.5 percentage points from fiscal 2025 (−79.7%). Over the past ten years it has ranged from −82.4% (fiscal 2023) to 261.2% (fiscal 2024); the current reading is higher than 18% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of −0.80% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −79.7% | (340.88) |
| FY2024 | 261.2% | 343.54 |
| FY2023 | −82.4% | (35.16) |
| FY2022 | −47.2% | (50.17) |
| FY2021 | 2.98% | (23.35) |
| FY2020 | 26.3% | 84.56 |
| FY2019 | −58.2% | (50.20) |
| FY2018 | −8.03% | (8.03) |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | (4.00) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| LQDA Liquidia Corporation compare | 131.8% |
| LNTH Lantheus Holdings, Inc. compare | 21.8% |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 17.6% |
| RDY Dr. Reddy's Laboratories Ltd compare | 6.60% |
| ALKS Alkermes plc compare | −0.02% |
| ELAN Elanco Animal Health Incorporated compare | −2.98% |
| HIMS Hims & Hers Health, Inc. compare | −32.0% |
| SUPN Indivior Pharmaceuticals Inc. compare | −337.8% |
| AMRX AMNEAL PHARMACEUTICALS, INC. | −53,107.2% |
| Drug Manufacturers Specialty & Generic industry median | −0.80% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on AMRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement